Journal article · 2025 · Open access

Pharmacogenomics in Personalized Medicine Approaches

Oscar Kovacs

International Journal of Life Sciences Biotechnology and Pharma Sciences · Published 1 September 2025 · DOI 10.62648/v21.i04.2025.pp10-18

Open PDFView at the publisherCite this paper

In brief

“Pharmacogenomics in Personalized Medicine Approaches” is a 2025 journal article by Oscar Kovacs, published in International Journal of Life Sciences Biotechnology and Pharma Sciences. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at International Journal of Life Sciences Biotechnology and Pharma Sciences.

Citations
0
References
18
Authors
1

Abstract

Pharmacogenomics--the study of how genetic variation influences individual drug response in terms of efficacy, toxicity,and dosing requirements--has transitioned from a research discipline to a clinical standard of care across oncology,psychiatry, cardiology, and infectious disease over the past two decades, driven by the declining cost of genotyping andthe accumulating body of clinically actionable pharmacogenomic (PGx) associations validated in prospective trials. Thisreview comprehensively surveys the current landscape of pharmacogenomics in personalised medicine, covering: themolecular basis of PGx variation in drug-metabolising enzymes (CYP450 family, UGT1A1, TPMT, DPYD), drugtransporters (SLCO1B1, ABCB1), and drug targets (VKORC1, EGFR, KRAS, HER2); clinical implementation evidencefrom landmark trials including CPIC guideline-supported drug-gene pairs; the expanding role of polygenic risk scores(PRS) in drug response prediction beyond single-variant pharmacogenomics; current clinical decision support integrationchallenges; and the regulatory and health economic framework for PGx-guided prescribing. Key clinically validatedexamples reviewed include: warfarin dosing guided by CYP2C9/VKORC1/CYP4F2 genotype (reducing serious bleedingevents by 31-43%); clopidogrel response prediction by CYP2C19 loss-of-function alleles (associated with 3.58-foldincreased MACE risk in poor metabolisers); DPYD genotyping before fluoropyrimidine chemotherapy (reducing severetoxicity from 35% to 4.7%); and HER2/KRAS/BRAF tumour genotyping directing targeted therapy selection in metastaticcolorectal and breast cancer. Remaining implementation barriers including incomplete population diversity in PGxreference datasets, clinical workflow integration complexity, and reimbursement heterogeneity across Europeanhealthcare systems are critically evaluated alongside emerging opportunities from direct-to-consumer genomics,preemptive panel genotyping, and AI-guided phenotype prediction.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kovacs, O. (2025). Pharmacogenomics in Personalized Medicine Approaches. International Journal of Life Sciences Biotechnology and Pharma Sciences. https://doi.org/10.62648/v21.i04.2025.pp10-18

MLA 9

Kovacs, Oscar. “Pharmacogenomics in Personalized Medicine Approaches.” International Journal of Life Sciences Biotechnology and Pharma Sciences, 2025. https://doi.org/10.62648/v21.i04.2025.pp10-18.

Chicago

Kovacs, Oscar. 2025. “Pharmacogenomics in Personalized Medicine Approaches.” International Journal of Life Sciences Biotechnology and Pharma Sciences. https://doi.org/10.62648/v21.i04.2025.pp10-18.

Harvard

Kovacs, O. (2025) ‘Pharmacogenomics in Personalized Medicine Approaches’, International Journal of Life Sciences Biotechnology and Pharma Sciences. doi:10.62648/v21.i04.2025.pp10-18.

IEEE

O. Kovacs, “Pharmacogenomics in Personalized Medicine Approaches,” International Journal of Life Sciences Biotechnology and Pharma Sciences, 2025, doi: 10.62648/v21.i04.2025.pp10-18.

BibTeX

@article{kovacs2025pharmacogenomics,
  title     = {{Pharmacogenomics in Personalized Medicine Approaches}},
  author    = {Kovacs, Oscar},
  journal   = {International Journal of Life Sciences Biotechnology and Pharma Sciences},
  year      = {2025},
  doi       = {10.62648/v21.i04.2025.pp10-18},
  url       = {https://doi.org/10.62648/v21.i04.2025.pp10-18}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • personalized medicine
  • drug-metabolizing enzymes
  • drug transporters
  • drug response prediction
  • polygenic risk score
  • clinical decision support
  • warfarin dosing

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Kovacs, O. (2025). Pharmacogenomics in Personalized Medicine Approaches. International Journal of Life Sciences Biotechnology and Pharma Sciences. https://doi.org/10.62648/v21.i04.2025.pp10-18

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at International Journal of Life Sciences Biotechnology and Pharma Sciences: sign in and open the PDF from this page.

Who wrote this paper?

Oscar Kovacs.

What is the DOI of this paper?

10.62648/v21.i04.2025.pp10-18, permanently at https://doi.org/10.62648/v21.i04.2025.pp10-18. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.